Millions more could benefit from using weight-loss jabs
The one surprising impact of weight loss jab Ozempic
Thousands of NHS patients are unable to access the weight-loss jab Mounjaro due to significant funding shortfalls and a slow roll-out across England.
Fewer than half of England's commissioning bodies have begun prescribing Mounjaro on the NHS, over two months after national guidance was issued.
Despite an estimated 3.4 million people who could potentially benefit, current NHS funding for Integrated Care Boards covers only a fraction of eligible patients, creating a 'postcode lottery' for care.
Experts warn that underfunding and poor communication are causing distress for patients and primary care, potentially exacerbating the obesity crisis and its associated costs.
The Health Secretary, Wes Streeting, has pledged to improve NHS access to weight-loss jabs, following price increases by Mounjaro's manufacturer in the private sector.